Has Megan McCormack received payments from drug or device companies?

Yes. Drug and device makers reported $7,273 in general payments to Megan McCormack across 382 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Megan McCormack did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Megan McCormack come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Megan McCormack

Psychiatric/Mental Health · Liberty, NYNPI 1497153308

Payments from drug & device makers

$7,273in general payments, 2019–2025

Across 382 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Otsuka America Pharmaceutical, Inc.$1K
Johnson & Johnson$592
Neurocrine Biosciences, Inc.$507
Teva Pharmaceuticals USA, Inc.$446
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$366
plus $2K from 15 others

What the payments were for

Food & beverage$7,17399%
Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	126	$2,322
Otsuka America Pharmaceutical, Inc.	54	$1,048
Johnson & Johnson	23	$592
Neurocrine Biosciences, Inc.	24	$507
Teva Pharmaceuticals USA, Inc.	33	$446
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	19	$366
Alkermes, Inc.	19	$336
Indivior Inc.	16	$303
Axsome Therapeutics, Inc.	15	$299
Braeburn Inc.	13	$268
Orexo US, Inc.	12	$226
Sunovion Pharmaceuticals Inc.	7	$136
E.r. Squibb & Sons, L.L.C.	5	$108
Vanda Pharmaceuticals Inc.	3	$82
Biogen	2	$52
Corium, LLC	4	$50
Supernus Pharmaceuticals, Inc.	2	$39
Jazz Pharmaceuticals Inc.	2	$39
Lundbeck LLC	1	$21
Ironshore Pharmaceuticals Inc.	1	$17
Idorsia Pharmaceuticals US Inc	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,273 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Abilify MaintenaAripiprazole	17	$47,434
VraylarCariprazine Hcl	24	$36,682
RexultiBrexpiprazole	21	$29,947
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	34	$3,883
Aripiprazole	59	$2,672
Duloxetine Hcl	105	$2,339
Alprazolam	126	$1,442
Quetiapine Fumarate	42	$1,137
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	45	$780
Naltrexone Hcl	18	$750
Hydroxyzine Pamoate	67	$654
Hydroxyzine Hcl	24	$652
Lamotrigine	58	$614
Oxcarbazepine	17	$603
Eszopiclone	21	$548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti	$1,048	$77,38138 claims
AbbVieVraylar	$2,322	$36,68224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Liberty

Glenn HannDansville$1.3M
Tammy RussoNiskayuna$568K
Carrie EdickSchenectady$484K
Eric SpronzCentereach$448K
Terry Jo Brooks-DevlinTonawanda$176K
Kevin SiewersStaten Island$155K
Daniel BreeyearNiskayuna$149K
Mary OlsonNew York$142K
Elijah StevensBinghamton$131K
Kayanna JonasFar Rockaway$93K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →